ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,751,620 | -11.7% | 433,000 | 0.0% | 11.84% | -18.2% |
Q2 2023 | $13,310,420 | -14.7% | 433,000 | 0.0% | 14.48% | -20.5% |
Q1 2023 | $15,600,990 | -14.6% | 433,000 | -6.3% | 18.22% | -8.9% |
Q4 2022 | $18,258,240 | -12.9% | 462,000 | -11.5% | 20.01% | -6.9% |
Q3 2022 | $20,964,000 | -12.8% | 521,750 | -8.7% | 21.48% | +1.3% |
Q2 2022 | $24,030,000 | -18.5% | 571,588 | -24.5% | 21.21% | -4.2% |
Q1 2022 | $29,488,000 | -8.2% | 756,874 | -6.1% | 22.15% | -5.0% |
Q4 2021 | $32,118,000 | +26.7% | 805,982 | +14.9% | 23.31% | +13.6% |
Q3 2021 | $25,346,000 | -13.1% | 701,323 | -1.4% | 20.53% | -13.2% |
Q2 2021 | $29,169,000 | +4073.0% | 711,623 | +4341.3% | 23.64% | +2870.4% |
Q1 2021 | $699,000 | -29.2% | 16,023 | -18.7% | 0.80% | -30.7% |
Q4 2020 | $987,000 | +0.7% | 19,718 | -15.3% | 1.15% | -6.4% |
Q3 2020 | $980,000 | +129.5% | 23,288 | +149.7% | 1.23% | +129.1% |
Q2 2020 | $427,000 | – | 9,328 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
Brown University | 621,759 | $22,470,000 | 3.05% |
Graypoint LLC | 610,584 | $22,067,000 | 2.71% |